Summary. In diarginylinsulin two arginine residues are located at the C-terminal end of the B-chain (Arg B31 and ArgB32). This accounts for a shift of the isoelectric point from pH 5.4 in native insulin to pH 7.0 in diarginylinsulin leading to pharmacodynamic characteristics of an intermediate acting insulin when administered s. c. as pH 4.0-5.0 solution. We have investigated insulin receptor binding and biological activity of biosynthetic human diarginylinsulin in human adip0-cytes and compared to native insulin and proinsulin. Association-and dissociation studies of insulin receptor binding revealed no differences for diarginylinsulin and native insulin. In competition studies under steady-state binding conditions, half-maximal displacement of tracer occurred at 352 + 33 pmol/1, 337 • 32 pmol/1 and 3640 + 480 pmol/1 for diarginylinsulin, insulin and proinsulin, respectively. The biologic potency of human diarginylinsulin was evaluated by the ability to stimulate D-glucose transport and by the assessment of the antilipolytic activity. Activation of D-glucose transport was half-maximal at 49.6 + 5.4 pmol/1 (diarginylinsulin), 44.8 _+ 5.8 pmol/1 (insulin) and at 476.7 + 134.3 pmol/1 (proinsulin). Half-maximal inhibition of lipolysis occurred at 13.9 + 3.4 pmol/1, 15.4 + 2.9 pmol/1 and 138.4 + 38.6 pmol/1, respectively. In conclusion, diarginylinsulin has almost identical insulin receptor binding characteristics and full biological activity in vitro compared to native insulin. This pharmacodynamically intermediate acting insulin preparation is therefore of potential therapeutical value.
In the bioconversion process of proinsulin to insulin several intermediate products physiologically occur. Diarginylinsulin is one of these intermediate metabolites and differs from native insulin by two remaining arginine residues at the C-terminal end of the B-chain [1] [2] [3] [4] [5] [6] (Fig. 1) . The two arginine residues at the C-terminal end of the B-chain in diarginylinsulin account for a shift of the isoelectric point from pH 5.4 in native insulin to pH 7.0 in diarginylinsulin [4] .
Diabetic patients receiving daily s.c. injections of insulin containing protamine appear to have a 40 to 50-fold increase in the risk of life-threatening reactions when given protamine i.v. for reversal of heparin anticoagulation during vascular surgery, cardiac catheterization or dialysis [8, 9] .
Attempts have been made to find an insulin analogue which retains full biological activity and has an intermediate or long-lasting action without the addition of a retardant. Due to the shift of the isoelectric point to pH 7.0 diarginylinsulin is least soluble at a physiological pH. When this insulin analogue is injected s.c. as pH 4.0-5.0 solution it has the pharmacodynamic characteristics of an intermediate acting NPH-insulin preparation.
However, previous studies revealed a reduced biological activity of porcine diarginylinsulin [7, 10, 11] . By application of recombinant DNA-technology biosynthetic human diarginylinsulin became available. The in vitro bi- 1 . Scheme of the proinsulin molecule. Diarginylinsulin occurs an the bioconversion process of proinsulin to insulin and differs from native insulin by two remaining arginine residues at the C-terminal end of the B-chain ological activity of the human diarginylinsulin has not yet been investigated in isolated human adipocytes. In this study we describe the in vitro characteristics of this insulin analogue with respect to insulin receptor binding, degradation, activation of D-glucose transport and inhibition of catecholamine stimulated lipolysis. Biosynthetic human diarginylinsulin is compared to native human insulin and biosynthetic human proinsulin.
Subjects, materials and methods

Mawrials
Crystalline human diarginylinsulin and native human insulin as well as the respective ([~25I]TyrA14)-monoiodinated insulin preparations (specific activity 340 mCi/mg) were provided by Hoechst AG (Frankfurt, FRG). Biosynthetic human proinsulin and radiolabelled ([~25I]Tyr79)-proinsulin (specific activity 216 mCi/mg) were a gift from the Eli Lilly Laboratories (Indianapolis, Ind., USA). Proinsulin has a different numerical sequence of the carboxyterminal amino acids than insulin because of the connecting peptide (C-peptide). In fact the iodination of the tyrosine residue at position 79 in proinsulin is equivalent to the iodinated tyrosine in position A14 after cleavage of the C-peptide [12, 13] . Iodinafion of the tyrosine residue in position A14 (diarginylinsulin, native insulin) or 79 (proinsulin) does not influence receptor binding characteristics or biological activity [14] [15] [16] .
Potency and purity of all investigated insulins were checked by HPLC according to methods described in the United States pharmacopoea (USP XXI). No cocrystallization was detectable by HPLC.
Crude collagenase was obtained from Sigma (type II, lot 102 F-6805). Human serum albumin was purchased from Behringwerke (Marburg, FRG). U-14C-D-glucose (specific activity 270 mCi/mmol) was obtained from Amersham (Braunschweig, FRG), phloretin from Sigma (St. Louis, Mo., USA), silicone oil (density 0.97 g/ml) from Serva Feinbiochemica (Heidelberg, FRG). All other chemicals were purchased from Merck (Darmstadt, FRG).
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Hepes buffer (10 mmol/1 Hepes, 50 g/1 human serum albumin, pH 7.4) at 37 ~ C. Each 12SI-labelled ligand (final concentration 20 pmol/1) was incubated with and without increasing amounts ofunlabelled diarginylinsulin, native insulin or proinsulin, respectively. The reaction was stopped by adding 10 ml of chilled 0.154 mol/1 NaC1 and subsequent centrifugation through silicone oil [18, 19] . Non-specific binding was measured by incubating tracer in the presence of a large excess of unlabelled insulin. Non-specific binding accounted for 9.7 + 1.6% (diarginylinsulin), 9.7 _+ 1.4% (native insulin) and 24.4 + 2.6% (proinsulin) of the cell-bound fraction at tracer concentration.
For association studies the lZSI-labelled ligands were incubated for the time indicated (1 rain to 240 min) and the reaction was terminated as described above. At each time point the non-specific binding was measured and subsequently subtracted from the corresponding data for total binding. Dissociation rates were determined by first preincubating isolated human adipocytes at 37 ~ C with either ([l~SI]TyrAle)-diarginylinsulin or ([125I]Tyra14)-insulin for 90 min to achieve steady-state binding conditions. Each incubation mixture was then centrifuged for 60 s and the infranatant removed. The adipocytes were rapidly washed twice by diluting to the original volume with buffer at 4 ~ C and repeating the centrifugations and aspirations. After the third aspiration, the cells were diluted to the orginal volume either with buffer alone or buffer to which either diarginylinsulin, native insulin or proinsulin at a final concentration of 0.2 gmol/1 was added (22 ~ C). At this hormone concentration a maximal effect of 125I-insulin dissociation is reported [20, 21] . The reaction was stopped at the times indicated (10 min to 180 rain) and cell-associated radioactivity was determined [21] . Results are expressed as percentage specific binding per 10 cm 2 plasma membrane surface area [22, 23] .
Total degradation (cellular and extracellular) of
)-proinsulin was assessed by the trichloracetic acid (12% weight/volume) precipitation method [24] . Extracellular degradation (as assessed in the presence of 0.1 gmol/1 insulin accounted for less than 15% of the total degradation for all three investigated insulins.
Measurement of insulin stimulated glucose uptake Preparation of isolated adipocytes
Subcutaneous adipose tissue (about 4-5 g) was obtained from the abdomen of patients undergoing elective gastroenterological surgery. No subject suffered from any endocrine or metabolic disorder or was taking drugs known to affect metabolism. Impaired glucose tolerance was excluded by measuring the fasting blood glucose concentration and the 2 h value after a 75 g oral glucose load according to World Health Organisation criteria [17] . The study was approved by the local ethical committee in accordance with the Declaration of Helsinki and informed consent was obtained from the patients.
The adipose tissue was finely chopped and incubated for 90 min at 37 ~ C in a Hepes buffer (pH 7.4), containing human serum albumin (25 g/l) and collagenase (0.5 g/l). The isolated adipocytes were subsequently washed five times in a Hepes buffer containing 50 g/1 human albumin [18, 19] . The diameters of adipocytes (n = 200) were measured at 200-fold magnification using an eyepiece micrometer. Surface area and volume were calculated for every cell diameter. The cell diameter of the isolated fat cells averaged 102 + 7 pm.
Initial D-glucose uptake was measured using the method described by Pedersen and Gliemann [25] and modified by Zeuzem and Taylor [26] . Human adipocytes (40 gl cell suspension with an adipocyte volume fraction of 0.40, i. e. about 0.8 x 106 cells/ml) were preincubated with and without increasing concentrations of diarginylinsulin, native insulin or proinsulin for 180 min. The incubation was started by a direct injection of 12 pl U-14C-D-glucose into the cell suspension (final concentration 20 gmol/l) and then stopped by the addition of 3 ml of 154 mmol/1 NaC1, containing 0.3 mmol/1 phloretin, pH 7.4. Silicone oil was layered on the surface and the tubes were centrifuged within 2 min for 90 s at 3000 g. The cell pellet was then immediately harvested and added to 5 ml scintillation fluid.
Extracellular trapped radioactivity was measured by adding 3 ml of the phloretin solution to the cell suspension before incubation with U-~4C-D-glucose and subsequently subtracted from all observed values. Results are expressed as pmol D-glucose taken up per 10 cm 2 plasma membrane surface area per 20 s [23] . The coefficient of variation of the assay was 9.0% for basal and 11.4% for maximal uptake.
Measurement of the antilipolytic insulin effect Insulin receptor binding and degradation
Insulin receptor binding studies to isolated fiuman adipocytes (300 gl cell suspension with an adipocyte volume fraction of 0.05, i.e. about l xl05cells/ml cell suspension) were performed in a Human adipocytes (500 ~tl cell suspension with an adipocyte volume fraction of 0.15, i. e. about 0.3 x 106 cells/ml) were preincubated with and without increasing concentrations of diarginylinsulin, native insulin and proinsulin for 180 rain at 37 ~ C to achieve steady-state binding conditions. Lipolysis was stimulated by noradrenaline Subsequently the cells were centrifuged through silicone oil and the infranatant was sampled. Glycerol release into the medium was measured using an enzymatic method [27] . Results are expressed as nmol glycerol released per 100,000 cells per 60 rain [23] .
Statistical analysis
All results are presented as mean + SEM. Statistical analysis was performed using Student's paired t -test.
Results
Steady-state binding
To determine when steady-state binding conditions were achieved, the time course of binding for ~25I-diarginylinsulin, 12sI-insulin and 125I-proinsulin (each concentration 20 pmol/1) were studied in parallel at 37 ~ C. In isolated human adipocytes internalization and degradation of the insulin is minimal even at physiological temperatures [18] . These binding studies therefore reflect primarily the association of each insulin to the cell surface receptors. 125I-diarginylinsulin reached half-maximal binding at 19.3 +3.1 min compared to 19.8+2.1 min for native insulin and 40.0 +4.1 min for proinsulin. 125I-diarginylinsulin reached 87% of its maximal binding at 60 min and maximal binding at 90 min. Maximal binding was maintained at least up to 4 h. Native ~25I-insulin reacted similarly, reaching maximal binding also at 90 min. However, human proinsulin attained steady-state binding conditions much slower than diarginyl-and native insulin. Under identical conditions, ~25I-proinsulin reached 47% of its maximal binding at 60 min and maximal binding at 180 min (Fig. 2) . For all competition studies of insulin receptor binding we therefore used an incubation period of 180 min to ensure steady-state conditions for all investigated insulins. 
Kinetic analysis
The calculated association rate constant [28] ka was 1.9 x 108 tool/l-lmin-1 for diarginylinsulin compared to ka = 1.3 x 108 mol/1-1min 1 (insulin) and ka = 0.01 x 108 M-lmin-1 (proinsulin) (Fig. 3) . The difference between diarginylinsulin and insulin was not significant (p > 0.1). The effect of unlabelled diarginylinsulin, insulin and proinsulin on the dissociation of ([125I]Tyra14)-diarginylinsulin (Fig.4) and ([125I]Tyra14)-insu|in (data not shown) were investigated. The dissociation curves of diarginylinsulin and native insulin were almost identical with a halftime of dissociation of 29.8 + 4.2 min and 28.6 + 5.6 min, respectively. The kd for dissociation were 2.5 x 10 2 minand 2.7 x 10 -2 min -~, respectively. Unlabelled diarginylinsulin and native insulin accelerated the dissociation of the corresponding 125I-labelled ligand when compared to the dissociation due to dilution only. Half-maximal disso- binding between diarginyl-and native insulin was not significant (p > 0.1).
The displacement curves for diarginyl-and native insulin were similar. Half-maximal displacement of tracer occurred at 352+33pmol/1, 337+32pmol/1 and 3640 + 480 pmol/1 for diarginylinsulin, insulin and proinsulin, respectively (Fig. 5 ). Scatchard analysis [29] of the binding data revealed curvilinear plots for all three investigated insulins. There were no differences between diarginylinsulin and insulin concerning the slopes of the high affinity portions of the plots. As anticipated, the abscissal intercepts (computer modelled, Dr. Schloos, Department of Pharmacokinetics, University of Frankfurt, FRG) yielded similar numbers of receptor sites per cell membrane surface area (7.2, 7.7 and 8.2 fmol per 10 cm 2 cell membrane surface area, respectively), indicating that the investigated three ligands bind to a similar number of receptors. The differences between diarginylinsulin and proinsulin were most marked for the high affinity portions of the plots, expressing the marked decrease of the receptor binding affinity of proinsulin.
Degradation
As measured by solubility in trichloracetic acid 1.5% of ([125I]Tyra14)-diarginylinsulin, 1.3% of ([125I]TyrA14)-insutin and 0.8% of ([125I]TyrY9)-proinsulin was degraded per i x 105 cells/ml per 60 min. curve for diarginylinsulin and native insulin. The dose-response curve of proinsulin is shifted to the right, indicating a reduced sensitivity but no decrease in responsiveness (Fig.6 ).
Insulin receptor binding
Anti-lipolysis
The glycerol release for noradrenaline and caffeine stimulated lipolysis was 1086 + 122 nmol per 100,000 cells per 60 rain. Half-maximal inhibition of lipolysis occurred at 13.9 + 3.4 pmol/1 (diarginylinsulin), 15.4 + 2.9 pmol/1 (insulin) and 138.4 + 38.6 pmol/1 (proinsulin). Maximal inhibition of lipolysis was observed at 814 +229 pmol/1, 943 + 307 pmol/1 and 75,714 + 19,615 pmol/1, respectively. No significant differences were found for the maximal inhibition of lipolysis (59.4+6.9%, 61.3+8.8% and 54.5 + 8.3%) nor the paradoxical effect of the insulins at high concentrations in stimulating lipolysis (Fig. 7) .
Discussion
The polypeptide chain of proinsulin is ordered as follows: NH2 -B-chain -Arg -Arg -C-peptide -Lys -Arg -A-chain -COOH (Fig. 1) . The conversion of proinsulin to insulin in the B-cells of the pancreas occurs by a branched pathway involving the formation of Arg65/Gly66-split proinsulin and Arg32/Glu33-split proinsulin, the latter being the preferential cleavage pathway (about 3 to 1) [5, 30] . The next step in the bioconversion process is the formation of des-Lys 64, Arg65-proinsulin and des-Arg31, -Arg32-proinsufin (des-dipeptide proinsulin intermediates). Cleavage of either intermediate by a trypsin-like endoprotease at the remaining paired dibasic amino acid conversion site, followed by the action of a carboxypeptidase B-like exoprotease to remove COOH-terminal basic residues, yields insulin, C-peptide and stoichiometric quantities of free lysine and arginine. During the last conversion steps of the des-Lys 64, Arg65-proinsulin diarginyland monoarginylinsulin occur as intermediates [3, 12] . The biological activities of several derivatives (conversion intermediates) of human proinsulin containing peptide bond cleavages or peptide deletions in the connecting peptide region have been investigated by Peavy et al. [31] . At high concentrations each derivative produced the same maximal response. Differences in the relative potency of these analogues, as indicated by the concentration required to produce a half-maximal response, generally agreed with the differences in receptor binding affinity. Interestingly, an apparent discrepancy was described for the des-[Glu33-LeuS6]-proinsulin. This analogue demonstrated a receptor binding affinity 27 times that of human proinsulin, but a biological activity only nine times that of proinsulin [31] . Des-[Glu33-Leu56] -proinsulin differs from diarginylinsulin only by nine amino-acids, which remain at the NH2-terminal end of the A-chain (Ala 57 to Arg65). In the present study, however, no differences were observed between receptor binding affinity and biological potency for the diarginylinsulin. The relative binding affinity of human proinsulin was 9.7% compared to diarginylinsulin, while the relative biological potencies for stimulating glucose-transport and inhibiting lipolysis were 10.4% and 10.0%, respectively.
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,-, 900- [34, 35] . The almost identical receptor binding affinity of biosynthetic human diarginylinsulin and native insulin implies that the substitution of Arg B31 and Arg B32 does not affect the binding region and makes conformational changes of this region unlikely.
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Kinetic studies showed no differences in the association rate between diarginylinsulin and native insulin. Both ligands were capable of accelerating the dissociation of either 125I-diarginylinsulin or 125I-insulin. These data suggest that diarginylinsulin is able to exhibit negative cooperative effects to a similar extent as native insulin. Studies with modified insulin analogues have defined the C-terminal end of the B-chain and the position Ash A2~ as most important for the potency of an insulin analogue to induce negative cooperative effects [36] . The substitution of two further amino-acids at the C-terminal B-chain as in the diarginylinsulin did not influence the negative cooperative properties.
Various chemical substitutions at the COOH-terminal end of the B-chain, e.g. with acetyl residues or butyloxycarbonyl (BOC) derivatives, were reported to cause a 25-56% decrease in potency [33] . In previous studies the biological activity of porcine diarginylinsulin was found to be reduced by 11 to 60% compared to native insulin [7, 10, 11, 32] .
The results of biosynthetic human diarginylinsulin in this study are in contrast to these previously reported data of porcine diarginylinsulin. However, most of the studies on the biological activity of porcine diarginylinsulin were performed ten or more years ago. The possibility exists that a small amount of contamination with proinsulin or partially cleaved proinsulin had been present, therefore explaining the reduced activity of porcine diarginylinsulin found in these studies. Native porcine and human insulin differ only by one amino acid (alanine and threonine in position B30). The biological activity of both insulins is equivalent. Therefore species differences as an explanation of the described differences appear to be unlikely. However, the two arginine residues are substituted at the position B30. It remains questionable whether the addition of two arginine residues at Ala B3~ instead ofThr B3~ can lead to a reduced biological activity.
The reported relative potencies of human proinsulin in vitro range between i and 16% that of native insulin [10, 12, 20, 37, 38] . In this study, using isolated human adipocytes, we observed a relative potency of 9.3% for receptor binding, 9.4% and 11.1% for activation of D-glucose transport and inhibition of lipolysis, respectively.
Measurement of total degradation showed no difference between ~25I-diarginylinsulin and 125I-insulin. The first step of insulin degradation may be mediated by a "insulin-specific protease" [12] . No difference in substrate activity of an insulin-specific protease was reported for porcine diarginylinsulin and insulin, the ability of the enzyme to degrade proinsulin, however, was negligible [39] . In our study the degradation of 125I-proinsulin was reduced in comparison to diarginylinsulin and native in-S. Zeuzem et al.: Human diarginylinsulin sulin. Studies of 125I-proinsulin internalization and degradation in rat fat cells by Podlecki et al. have suggested that internalization of receptor bound proinsulin proceeds to a greater degree than does insulin, but once proinsulin is internalized the rate of degradation was also found markedly reduced compared to insulin [20] .
In comparison to insulin, little attention has been paid to the immunogenicity of retardants. Protamine, a commonly used retardant of insulin absorption, is a basic polypeptide. Sera from patients treated with different types of protamine-insulin showed a high prevalence of circulating IgG-antibody to protamine. Rosenthal found that some protamine-insulin treated patients had responded immunologically to protamine as judged by the lymphocyte proliferation test [41] . In diabetic patients treated with protamine-insulins, the increased risk of serious reactions when i.v. protamine was given appeared to be caused largely by antibody-mediated mechanisms [8] . In a study by Kurtz et al. a relationship between insulin and protamine antigenicity was shown, suggesting that the protamine-insulin complex is itself immunogenic [40] . In several reports local and systemic reactions specifically to protamine and zinc have been described [42] [43] [44] [45] [46] . However, the actual percentage of diabetic patients in whom additives, such as protamine or zinc, are a cause of "insulin" allergy is unknown.
In conclusion, biosynthetic human diarginylinsulin and native insulin have almost identical in vitro bioactivities in isolated human adipocytes. Further investigations concerning the metabolic activity and the immunogenicity of diarginylinsulin in vivo as well as detailed absorption kinetic studies are required. By application of recombinant DNA technologies, it is possible to prepare large quantities of human diarginylinsulin. Thus, biosynthetic diarginylinsulin is a potential candidate for an intermediate acting insulin preparation containing no retarding substances.
